Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

GoHealth (GOCO) Cash & Equivalents (2020 - 2025)

GoHealth's Cash & Equivalents history spans 6 years, with the latest figure at $32.1 million for Q3 2025.

  • For Q3 2025, Cash & Equivalents fell 9.71% year-over-year to $32.1 million; the TTM value through Sep 2025 reached $32.1 million, down 9.71%, while the annual FY2024 figure was $40.9 million, 54.94% down from the prior year.
  • Cash & Equivalents for Q3 2025 was $32.1 million at GoHealth, down from $35.6 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $215.4 million in Q3 2022 and bottomed at $14.1 million in Q2 2024.
  • The 5-year median for Cash & Equivalents is $40.9 million (2024), against an average of $70.9 million.
  • The largest YoY upside for Cash & Equivalents was 451.56% in 2023 against a maximum downside of 87.75% in 2023.
  • A 5-year view of Cash & Equivalents shows it stood at $84.4 million in 2021, then crashed by 80.48% to $16.5 million in 2022, then soared by 451.56% to $90.8 million in 2023, then plummeted by 54.94% to $40.9 million in 2024, then decreased by 21.61% to $32.1 million in 2025.
  • Per Business Quant, the three most recent readings for GOCO's Cash & Equivalents are $32.1 million (Q3 2025), $35.6 million (Q2 2025), and $22.2 million (Q1 2025).